Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate two, orally administered, investigational agents - PF-06865571
(DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor).
This study is specifically designed to evaluate the effect of a range of doses of DGAT2i
alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed
histologically (via liver biopsy).